第 23 屆年度Medtech MVP
Tackling Medtech's Timeliest Issues and Opportunities
應對醫療技術最及時的挑戰和機遇
2024年6月17～18日
第23屆Medtech MVP是一年一度邀集全美主要醫療科技行業領先創新者、投資者和高管齊聚的會議。 該會議的特點是可與醫療技術創新者和商業領袖就相關主題進行坦誠的討論（小組討論和一對一對話），以及在緊密聯繫的社群中建立廣泛人脈。 各種主題演講和小組討論提供了富有洞察力和資訊量的見解和建議，這是Medtech MVP計劃多年來取得成功的原因。今年的焦點將放在醫療科技的DEI、融資、慢性疾病領域的技術創新、軟硬體的融合、FDA 臨床試驗小組、反向專題小組討論、主題演講、座談會和公共討論等及時主題上。通過分享創新想法和建立人際關係，繼續幫助推動產業發展。
6月17日星期一
Registration Open
Organizer's Welcome Remarks
Breakthrough Devices: A Breakthrough for Innovators and Investors?
Christian Johnson, CEO, ScoutMedix
Is Breakthrough Device Designation actually a breakthrough for device innovators, investors, and patients? Does the program expedite timely access to the US market, reduce investor capital risk and increase investor confidence, and elevate brand value for your medical device or portfolio? Should you pursue Breakthrough designation for your medical device or stay course with a traditional regulatory pathway? In this session, MedTech innovators, investors, and former regulators will provide you guidance on whether the Breakthrough Device Program will bring value to your device or portfolio investment based on their experience in the program, industry research, and novel insights from the 95 devices that have obtained FDA market authorization to date.
Mark Domyahn, Partner, JD Lymon
Michael John, VP Head of Cardiovascular Regulatory Affairs, MCRA LLC
Amrinder Singh, Partner, Vensana Capital
Kwame Ulmer, Managing Partner, MedTech Impact Partners; former FDA Branch Chief and Deputy Director
Lisa Wipperman-Heine, Board Director and Medtech Executive
Join us for the Avio MedTech Pitch Contest 2024, where the top three finalists will present their innovative solutions to a panel of expert judges in a tightly scheduled showdown. Experience back-to-back pitches followed by engaging Q&A sessions, leading up to the highly anticipated announcement of the winner. Don't miss this electrifying finale, filled with groundbreaking ideas and insights into the future of medical technology.
BREAKOUT DISCUSSION:Commercializing Digital Health Tech SolutionsShaye Mandle, Exec Director, AdvaMed Digital Health Tech, AdvaMed
Digital medtech platforms leveraging AI are delivering advanced care for patients and creating powerful solutions for providers. This session will present the investor and company perspective on market access strategies for data and AI in a provider environment.
David Kereiakes, Managing Partner, Windham Venture Partners
David Schummers, CEO, Apella
Networking Welcome Reception
Close of Day
6月18日 星期二
Registration and Morning Coffee
Organizer's Welcome Remarks
Sponsored Presentation (Opportunity Available)
KEYNOTE FIRESIDE CHAT: Healthcare Executive Interview
Ashley McEvoy, Former EVP, Worldwide Chair of MedTech, Johnson & Johnson
Ashley McEvoy had an amazing 27-year career journey at Johnson & Johnson, most recently as EVP and Worldwide Group Chairman of J&J MedTech. Today, we will discuss Ashley's optimism for the future of the MedTech industry, her J&J journey and experience executing a massive digital transformation for J&J MedTech, and finally her lessons for future generations of leaders.
Renee C Ryan, Independent Director, Audit Committee, RefleXion Medical
Early-Stage Panel: Strategic Engagement & Raising Capital
Jeff Peters, Venture Partner, Healthcare, OrbiMed Advisors LLC
The Early-Stage Capital Panel will explore the best practices or tips for improving access to early institutional financing. What are the common mistakes? Is partnering with a Strategic early on viable? The panel will feature perspectives from entrepreneurs, venture capitalists, and strategics.
Maria Berkman, MD, Director & Head of MedTech, Broadview Ventures
Christopher Kaster, Managing Partner, Cadence Healthcare Ventures
Patrice Kloss, JD, Partner, Fox Rothschild LLP
Rick Sanghera, President & CEO, AtaCor Medical
Darshana Zaveri, Founder and Managing Partner, Catalyst Health Ventures
Interview with Medtech MVP 2024 Award Recipient
Raymond W. Cohen, CEO, Axonics, Inc.
The MVP Award recognizes an individual for extraordinary contributions to a medtech company that has successfully advanced an important new product and delivered strong financial returns. This year's award honors Raymond Cohen, CEO of Axonics for his visionary leadership and innovative solutions that have propelled Axonics to the forefront of the industry. In an exclusive interview with Geoff Pardo, General Partner, Gilde Healthcare, the pair will explore Axonic’s groundbreaking technology, the importance of neuromodulation, and Ray’s storied career, including focusing on key decisions that led him to become an entrepreneur and ultimately the leader of one of the most successful venture-backed medtech companies of our time.
Geoffrey Pardo, General Partner, Gilde Healthcare
Networking Coffee Break
BREAKOUT DISCUSSION:High-Tech Meets Med-Tech - Privacy and FDA Regulatory Considerations for Connected Medical DevicesSpeaker to be Announced, Gardner Law
Nathan Downing, Sr Attorney, Gardner Law
Nathan Downing and Paul Rothermel will discuss regulatory and privacy considerations for connected devices, including those utilizing artificial intelligence. In these fast-growing areas of the medical device industry, companies need to contend with FDA’s increasing focus on cybersecurity and the ever-changing state of privacy laws.
BREAKOUT DISCUSSION:Emerging enterprise risk considerations and effective approaches to risk managementMario Prohasky, Director, Baker Tilly
Proactive and effective risk management remains a challenge with evolving compliance requirements and a constantly shifting business environment. We will focus on key emerging risk areas such as AI technology, the use of digital and data assets, the need for ESG risk mitigation, and new compliance regulations in global markets. We will also analyze how companies bring disparate risks into a cohesive enterprise risk management program and manage risk proactively while providing business value.
BREAKOUT DISCUSSION:Forecasting the Future: Leveraging Lessons from the Most Experienced Minds in Medical Device to Create a Viable Future.Frank Jaskulke, VP, Innovation, Head of Medical , Medical Alley
Christine Horton, Advisor to CAPITA3, President and CEO, Visura Technologies Inc
Thom Gunderson, Chair of Minneapolis Heart Institute Foundation Board of Directors, Former Managing Director, Piper Sandler
Kathleen Tune, Former Managing Partner at Thomas McNerney, Managing Partner, CAPITA3
Scott Ward, Former Chairman and CEO of Cardiovascular Systems, Inc. (acquired by Abbott in 2023), Founder, Raymond Holdings
Networking Lunch
Late-Stage Companies: M&A vs. IPO Debate
J.P. Peltier, Managing Director, Global Head, Healthcare Investment Banking, Piper Sandler
While the med tech IPO market has been dormant for the past 30 months, the sentiment of both investors and companies is changing. There are 40 plus private high growth med tech companies with the financial profile to consider an IPO path over the next 12 to 18 months. The same profile that qualifies these companies for IPO also makes them attractive acquisition targets ($50+M of sales, high growth, high margins). This panel will dive into the board room and discuss the decision making process of IPO, M&A or dual-path. We also have the opportunity to hear from one of the leading strategic consolidators in the med tech space on their views of the med tech landscape and implications of an open IPO window
Joshua Baltzell, Venture Partner, SightLine Partners LLC
Christopher E. Eso, Vice President, Global Head of Corporate and Business Development, M&A and Ventures, Medtronic
Garheng Kong, Founder & Managing Partner, HealthQuest Capital
Presentation to be Announced
Clinical/Regulatory Strategies for Commercial Success
Cynthia Yee, Partner, Vensana Capital
A strong foundation of clinical evidence is integral to commercial success, enabling a company to secure regulatory clearance, support reimbursement, drive physician adoption, and create a durable competitive advantage. This panel explores what it takes to establish a novel technology as the new standard-of-care, with focus on strategies for clinical trial design, execution, and data analysis/communication, as well as the resilience and adaptability needed when plans go awry.
James Eadie, MD, Managing Director, Sante Ventures
Margot Goodkin, Chief Medical Officer, SpyGlass Pharma
Sam Roosz, CEO, Crescendo Health
Stacey Pugh, CEO, Endogenex
Town Hall-Which Topics are Front-of-Mind?
Buzz Benson, Managing Director, SightLine Partners LLC
Jan Garfinkle, Managing Partner, Arboretum Ventures
Michael Kujak, President & CEO, Francis Medical
This interactive, engaging, and provocative session will explore topics that matter to you and your business. Our panel of industry veterans will share their ideas and points of view, but we want to hear from you! So please come ready to tee up issues you’d like to discuss and be prepared to engage with your peers as we efficiently unpack a variety of topics.
Networking Refreshment Break
Convergence of Software and Hardware
Aabed Meer, MD, Partner, Questa Capital
The panel offers a deep dive into the symbiotic relationship between software and hardware within the healthcare industry. From wearable devices to diagnostic tools, this intersection is reshaping patient care, treatment paradigms, and healthcare delivery. We will explore the transformative potential of this convergence and its implications for patient outcomes.
Andy Danielsen, Chair, Mayo Clinic Ventures
Sameer Jafri, CEO, Avive Solutions Inc.
Ron Li, Medical Director for Digital Health, Stanford Health Care Clinical Associate Professor of medicine, Stanford school of Medicine
Announcement of Pitch Contest Winner- Fireside Chat
Innovation in Chronic Disease Indications
Zack Scott, General Partner, Norwest Venture Partners
Kari Snaza, Co-Founder and President, Oasis Health Partners
Rebecca Seidel, Senior Vice President and President, Cardiac Ablation Solutions, Medtronic
Murthy Simhambhatla, PhD, CEO, SetPoint Medical
Closing Networking Reception
Close of Summit
* 活動內容有可能不事先告知作更動及調整。
